RT Journal Article SR Electronic T1 Serum D-dimer level in women with polycystic ovary syndrome JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.06.23.24308327 DO 10.1101/2024.06.23.24308327 A1 Hossan, S A1 Morshed, MS A1 Banu, H A1 Hasanat, MA YR 2024 UL http://medrxiv.org/content/early/2024/06/24/2024.06.23.24308327.abstract AB Background Women with polycystic ovarian syndrome (PCOS) have hyperandrogenemia and insulin resistance, which predispose them to prothrombotic conditions. D-dimer is a global marker of hemostatic dysfunction that has a contentious relationship with PCOS.Objective To assess the association of D-dimer with PCOS and its manifestationsMethods This case-control study enrolled 44 women with PCOS based on the International Evidence-based Guideline, 2018, and an equal number of matched healthy controls by convenient sampling. After obtaining informed consent, participants’ clinical data was taken, and fasting blood was drawn to measure glucose, lipid profile, hormones, and D-dimer. D-dimer was analyzed by latex immunofluorescence assay.Results The D-dimer levels and status were statistically similar between the study groups [PCOS vs. control: 0.11 (0.10-0.17) vs. 0.13 (0.10-0.22), median (IQR), p= 0.673]. D-dimer levels did not vary according to the different characteristics of women with PCOS (p>0.05). D-dimer levels had no significant correlations with various clinical and biochemical characteristics among women with PCOS (p>0.05).Conclusion D-dimer has no significant association with PCOS or its manifestations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPartial funding by Research & Development, BSMMUAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Registration no- 3582. BSMMU/2021/7642, date: 24/08/2021I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors